Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has announced the filing of a provisional patent application for the treatment of…

Source